Answers are grounded in this paper and cite their sources.
The Centers for Medicare and Medicaid Services (CMS) are currently negotiating prices with pharmaceutical manufacturers for the first 10 Part D drugs selected for Medicare drug price negotiation. Non-publicly available data, including the net prices of selected drugs and their therapeutic alternatives, will play a central role in the determination of the maximum fair prices (MFPs).
No takes yet. Share an insight, caveat, or question.
Hernandez et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: